Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | USP5 | P45974 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623570 | 0.92 | ESR2 (0.48) | ESR2USP5HDAC6ADRA1ASCD5 | |
| SCHEMBL8623573 | 0.92 | ESR2 (0.48) | ESR2USP5HDAC6ADRA1ASCD5 | |
| SCHEMBL8623567 | 0.92 | ESR2 (0.48) | ESR2USP5HDAC6ADRA1ASCD5 | |
| SCHEMBL14817246 | 0.87 | ESR2 (0.53) | ESR2USP5HDAC6ADRA1ASCD5 | |
| SCHEMBL10043342 | 0.86 | ABCB1 (0.38) | USP5HDAC6HTR2AHTR2CHTR2B | |
| SCHEMBL10043343 | 0.85 | ESR2 (0.41) | ESR2USP5HDAC6ADRA1AHTR2A | |
| SCHEMBL10071807 | 0.85 | ESR2 (0.42) | ESR2USP5HDAC6ADRA1ASCD5 | |
| SCHEMBL10072200 | 0.85 | ESR2 (0.42) | ESR2USP5HDAC6ADRA1ASCD5 | |
| SCHEMBL12975733 | 0.85 | ESR2 (0.41) | ESR2USP5HDAC6ADRA1AHTR2A | |
| SCHEMBL17827776 | 0.83 | HTR2A (0.42) | USP5HDAC6SCD5HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | HTR3D, KIF23, CCND3 | ESR2 2435/4885USP5 2406/4885HDAC6 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.